<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444662</url>
  </required_header>
  <id_info>
    <org_study_id>16518</org_study_id>
    <nct_id>NCT03444662</nct_id>
  </id_info>
  <brief_title>The Combination Effect of Citicoline and Omega-3</brief_title>
  <official_title>The Combination of Citicoline and Omega-3 on Attention in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Bio Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyowa Hakko Bio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the effects of Citicoline plus Omega-3 or Omega-3
      alone versus placebo on attention in non-demented healthy older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled trial. The investigators
      hypothesize that supplementation of Citicoline plus Omega-3 will improve attention in healthy
      adults age 55 years and older, compared to placebo. The study is designed as 3-arm, parallel
      group study comparing placebo, Omega-3 only, and Citicoline plus Omega-3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy (percent correct) on an attention task (Conners continuous performance test3)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores of Neuropsychological test battery from the Uniform Data Set</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as monitored by recording a comprehensive metabolic panel, complete blood count and prothrombin time-international normalized ratio</measure>
    <time_frame>16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma fatty acid levels</measure>
    <time_frame>16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apolipoprotein E genotype</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Dietary Supplement: Placebo supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognizin and Omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Dietary Supplement: Citicoline and Omega-3 supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Dietary Supplement: Omega-3 supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo supplement</intervention_name>
    <description>Cellulose and Sunflower oil</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citicoline and Omega-3 supplement</intervention_name>
    <description>Citicoline and Omega-3</description>
    <arm_group_label>Cognizin and Omega-3</arm_group_label>
    <other_name>Cognizin and Omega-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 supplement</intervention_name>
    <description>Cellulose and Omega-3</description>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Omega-3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 55 years or older

          -  If female, must be post-menopausal

          -  Non-demented

          -  Not depressed

          -  General health status that will not interfere with the participant's ability to
             complete the study

          -  No history of neurological disorder

          -  Screening laboratory values within normal limits or, if abnormal, deemed clinically
             insignificant by the investigator

          -  Sufficient English language skills to complete all testing

        Exclusion Criteria:

          -  Alzheimer's, Dementia or other neurological disease

          -  Fish intake of 6 ounce serving once a week 3 months prior to enrollment; Omega-3
             supplement intake (e.g. fish oil capsules, cod liver oil, or flaxseed oil) less than 3
             months prior to enrollment.

          -  Citicoline supplementation 3 months prior to enrollment

          -  Prescriptions medications:

               1. Anticoagulation therapy: Vitamin K antagonist: warfarin (Coumadin, jantoven),
                  Factor Xa inhibitors: rivaroxaban (xarelto), fondaparinux (arixtra), dibigatran
                  (pradaxa), apixaban (eliquis); Low molecular weight heparins: dalteparin
                  (fragmin), enoxaparin (lovenox)

               2. Dementia medications (e.g. anticholinesterase inhibitors, memantine)

               3. Diagnosis of Adult Attention Deficit Disorder (ADD) or Attention Deficit
                  Hyperactivity Disorder (ADHD) and/or taking stimulants (e.g. dextroamphetamine
                  sulfate, methylphenidate HCL, dextroamphetamine Sulf-Saccharate)

          -  Body Mass Index &gt; 30

          -  Enrollment in another treatment study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lynne Shinto, ND, MPH</last_name>
    <phone>(503) 494-5035</phone>
    <email>shintol@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Shinto, ND, MPH</last_name>
      <phone>503-494-5035</phone>
      <email>shintol@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Lynne Shinto, ND, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

